Biotech industry leaders added to the Board of Directors, bringing deep expertise in drug discovery, neuroscience clinical development, and ...

Bayko covers the Healthcare sector, focusing on stocks such as Travere Therapeutics, Vertex Pharmaceuticals ... Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the ...

Royalty Pharma's Q3 results show growth driven by strong portfolio performance and acquisitions. See why we recommend a buy ...

Q3 2024 Earnings Call Transcript November 6, 2024 Operator: Good day, and welcome to the Vertex Inc. Third Quarter 2024 ...

Crispr has already secured a historic first approval for a CRISPR/Cas9 drug and has several more potential blockbuster ...

These three emerging technology leaders are pioneering quantum computing, gene editing, and electric aviation.

The Cas nuclease market is on an upward trajectory, forecasted to grow from $2.75 billion in 2023 to $3.27 billion in 2024, at a CAGR of 18.9%. Key drivers include the rapid advancements in genome ...

Negative data cost AbbVie billions of dollars in market value and convinced analysts Bristol Myers had placed a better bet in ...

Kesmalea Therapeutics, a biopharmaceutical company developing a pipeline of novel therapeutics founded on the ability to transform large protein degraders into small molecules, today announced the ...

In another departure from its core focus on genetic medicines, Vertex Pharma has agreed ... a time when investors have been looking for business development. They note that competition in IgAN ...

Reliance Power, Nykaa, 3M India, Sula Vineyards, BASF India, Natco Pharma, and Rattanindia Enterprises are among other firms ...

America's pharmaceutical founding fathers Meanwhile in the USA, Pfizer was founded in 1849 by two German immigrants, initially as a fine chemicals business. Their business expanded rapidly during ...